Episode 0002: Myriad Genetics: Strategic outlook discussed in NYC research analyst day

In Myriad’s analyst day held in NYC on September 14, 2015, management discussed the outlook for several new growth drivers, and it addressed challenges faced in its legacy BRCA1/2 hereditary cancer genetic testing franchise. ¬†We explore what’s new, the ins and outs of each opportunity, and delve into the intricacies of companion diagnostics.